Skip to content

Netherlands logo

Main menu
    • About us
    • Our focus
    • Our products
    • Business development
    • Our leaders
    • Our culture
    • Policies & positions
    • Environmental, social & governance
    • Diversity, equity, inclusion & belonging
    • News
    • Media
  • Join our team

Contact Us

Back
Change Language
  • Nederlands
Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Organon launch in the media

Save Print

June 10, 2021 2:00 pm EDT

AMSTERDAM – Media in the Netherlands and Belgium have paid extensive attention to the return of the name Organon. On June 3, Organon (NYSE:OGN) celebrated its launch worldwide as the only company to focus on women’s health on such a large scale. In the Netherlands and Belgium, Organon has two production locations and two offices. Because the opening of the offices is only planned after the summer, the media came to Oss and Heist-op-den-Berg.

NOS: Organon from Oss on the NYSE

RTL: Organon gets a spot in S&P 500

NU.nl: ‘Contraceptive pill maker’ Organon returns to Oss after 12 years

NOS: The name Organon is back in Oss

BNR: Pharma company Organon back in Oss

Omroep Brabant: Well-known Organon logo show off again – ‘Hugely proud’

DTV Oss: Organon Organon officially back in Oss

RTV – Organon start as a new healthcare company in Heist-op-den-Berg

Gazet van Antwerpen – Heist branch of MSD continues as Organon: “No changes for employees”

What can we help you find?

Search for:
Netherlands logo
  • Forward-Looking Statement
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept